Eagle Asset Management Inc. Purchases New Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Eagle Asset Management Inc. bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 35,630 shares of the specialty pharmaceutical company's stock, valued at approximately $2,189,000. Eagle Asset Management Inc. owned approximately 0.17% of ANI Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth $106,000. Sei Investments Co. lifted its holdings in ANI Pharmaceuticals by 16.4% in the 1st quarter. Sei Investments Co. now owns 11,321 shares of the specialty pharmaceutical company's stock valued at $783,000 after acquiring an additional 1,594 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of ANI Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company's stock valued at $90,314,000 after purchasing an additional 17,460 shares in the last quarter. O Shaughnessy Asset Management LLC bought a new position in shares of ANI Pharmaceuticals during the 1st quarter valued at about $218,000. Finally, CANADA LIFE ASSURANCE Co grew its stake in shares of ANI Pharmaceuticals by 7.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 13,036 shares of the specialty pharmaceutical company's stock worth $900,000 after purchasing an additional 909 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on ANIP. StockNews.com lowered shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, September 7th. Truist Financial lifted their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a "hold" rating in a report on Tuesday, October 22nd. Raymond James upped their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a report on Wednesday, September 18th. Piper Sandler started coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an "overweight" rating and a $68.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $77.33.

ANI Pharmaceuticals Stock Down 1.3 %

ANI Pharmaceuticals stock traded down $0.78 during mid-day trading on Tuesday, hitting $57.86. The company's stock had a trading volume of 191,264 shares, compared to its average volume of 218,764. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81. The company has a market cap of $1.22 billion, a PE ratio of -105.29 and a beta of 0.71. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The firm's 50 day moving average is $58.36 and its 200 day moving average is $60.83.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $148.30 million during the quarter, compared to analysts' expectations of $144.37 million. During the same period last year, the company posted $1.05 earnings per share. The firm's quarterly revenue was up 12.5% compared to the same quarter last year. On average, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.